首页> 外文期刊>The journal of trauma and acute care surgery >Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study
【24h】

Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study

机译:低分子量肝素可预防脑外伤患者的静脉血栓栓塞安全吗?西方创伤协会多中心研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Venous thromboembolism (VTE) is a significant risk in trauma patients. Although low-molecular weight heparin (LMWH) is effective in VTE prophylaxis, its use for patients with traumatic intracranial hemorrhage remains controversial. The purpose of this study was to evaluate the safety of LMWH for VTE prophylaxis in blunt intracranial injury. Methods: We conducted a retrospective multicenter study of LMWH chemoprophylaxis on patients with intracranial hemorrhage caused by blunt trauma. Patients with brain Abbreviated Injury Scale score of 3 or higher, age 18 years or older, and at least one repeated head computed tomographic scan were included. Patients with previous VTE; on preinjury anticoagulation; hospitalized for less than 48 hours; on heparin for VTE prophylaxis; or required emergent thoracic, abdominal, or vascular surgery at admission were excluded. Patients were divided into two groups: those who received LMWH and those who did not. The primary outcome was progression of intracranial hemorrhage on repeated head computed tomographic scan. Results: The study included 1,215 patients, of which 220 patients (18.1%) received LMWH and 995 (81.9%) did not. Hemorrhage progression occurred in 239 of 995 control subjects and 93 of 220 LMWH patients (24% vs. 42%, p < 0.001). Hemorrhage progression occurred in 32 patients after initiating LMWH (14.5%). Nine of these patients (4.1%) required neurosurgical intervention for hemorrhage progression. Conclusion: Patients receiving LMWH were at higher risk for hemorrhage progression. We were unable to demonstrate safety of LMWH for VTE prophylaxis in patients with brain injury. The risk of using LMWH may exceed its benefit.(J Trauma Acute Care Surg. 2012;73: 625-628.
机译:背景:静脉血栓栓塞症(VTE)是创伤患者的重大风险。尽管低分子量肝素(LMWH)在预防VTE方面有效,但其在颅脑外伤患者中的使用仍存在争议。这项研究的目的是评估LMWH在钝性颅内损伤中预防VTE的安全性。方法:我们对钝性创伤引起的颅内出血患者进行了LMWH化学预防的回顾性多中心研究。包括年龄≥18岁,年龄≥18岁且至少进行过一次头颅计算机断层扫描的3次或2次以上的患者。曾接受过VTE的患者;损伤前抗凝住院少于48小时;用肝素预防VTE;或入院时需要进行的急诊胸部,腹部或血管外科手术。患者分为两组:接受LMWH的患者和未接受LMWH的患者。主要结果是在重复的头部计算机断层扫描中颅内出血的进展。结果:该研究包括1,215例患者,其中220例(18.1%)接受了LMWH,而995例(81.9%)未接受。 995名对照受试者中有239名发生出血进展,220名LMWH患者中有93名发生出血(24%比42%,p <0.001)。启动LMWH后有32例患者发生了出血进展(14.5%)。这些患者中有9名(4.1%)需要神经外科干预以治疗出血进展。结论:接受LMWH的患者出血进展的风险较高。我们无法证明LMWH预防脑损伤患者VTE的安全性。使用LMWH的风险可能会超过其益处。(J Trauma Acute Care Surg.2012; 73:625-628。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号